Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia.

European journal of haematology - 1 Feb 2021

Raghunathan Vikram, Fan Guang, Kittai Adam S, Okada Craig, Danilov Alexey V, Spurgeon Stephen E

Abstract excerpt

The treatment of chronic lymphocytic leukemia (CLL) has been transformed by the use of targeted small molecules inhibiting components of the B cell receptor (BCR) signaling pathway (Haematologica, 103, 2018 and e204; Curr Hematol Malig Rep, 14, 2019, 302). Chief among these is ibrutinib, an irreversible inhibitor of Bruton tyrosine kinase (BTK), which produces deep, durable responses in CLL with good tolerability...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Agammaglobulinaemia Tyrosine Kinase
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to High-Throughput Nucleotide Sequencing

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Molecular Targeted Therapy

Share to Phospholipase C gamma

Share to Protein Kinase Inhibitors

Share to Syk Kinase

Source

Identifiers

PMID: 33089525
DOI: 10.1111/ejh.13538

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A novel somatic PLCG2 variant associated with resistance to BTK and SYK inhibition in chronic lymphocytic leukemia.PMID 33089525Read ↗

Are BTK and PLCG2 mutations necessary and sufficient for ibrutinib resistance in chronic lymphocytic leukemia?Semantic proximity Read ↗

PLCG2 C2 domain mutations co-occur with BTK and PLCG2 resistance mutations in chronic lymphocytic leukemia undergoing ibrutinib treatment.Semantic proximity Read ↗

Hypermorphic mutation of phospholipase C, γ2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activationSemantic proximity Read ↗

Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice.Semantic proximity Read ↗

PLCG2 exon-skipped variants: insights into their potential role in chronic lymphocytic leukemia.Semantic proximity Read ↗

A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL).Semantic proximity Read ↗

Resistance mechanisms and approach to chronic lymphocytic leukemia after BTK inhibitor therapy.Semantic proximity Read ↗

BTK and PLCG2 remain unmutated in one-third of patients with CLL relapsing on ibrutinibSemantic proximity Read ↗

Resistance-Associated Mutations in Chronic Lymphocytic Leukemia Patients Treated With Novel AgentsSemantic proximity Read ↗

SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

BRUTON’S TYROSINE KINASE (BTK) MUTATIONS IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): A CLINICAL VIEW.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.